Yesterday, PolyMedix, Inc. announced the appointment of Steffen Helmling, Ph.D. as their new Vice President of Business Development. Dr. Helmling will be responsible for new development initiatives, such as partnering and licensing for PolyMedix’s products in development.
PolyMedix is a biotech company focused on developing new pharmaceuticals for the treatment of infectious diseases and cardiovascular disorders. PolyMedix’s lead antibiotic, MX-30063, is in Phase 2 clinical trials, and its lead heptagonist compound, PMX-60056, has completed Phase 1 trials. Their PolyCides products are intended to be used as additives to such items as paints, plastic and textile to create self-sterilizing surfaces.
Dr. Helmling’s previous position was at Noxxon Pharma, Inc., where he most recently served as Executive Vice President, Business Development. During his time at Noxxon, Helmling worked with such companies as Pfizer, Roche, and Eli Lilly. He has a Master’s in Biology from Bowling Green State University, and a Ph.D. in biochemistry from Tufts University.
“We are pleased to have Steffen join our management team,” said Nicholas Landekic, President and CEO of PolyMedix. “He brings an impressive background in negotiating licensing agreements, managing partnerships, and conducting market assessments. His expertise and track record of achievements will be a major asset as we advance our programs through the clinic and continue to explore opportunities for partnerships with pharmaceutical companies.”
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment